GO:0045345 positive regulation of MHC class I biosynthetic process: Antigen Presentation Pathway, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0045345 describes any process that activates or increases the frequency, rate or extent of the biosynthetic process that produces MHC class I molecules.
• MHC class I biosynthesis involves peptide loading, chaperone-assisted assembly, and trafficking to the cell surface, where MHC class I presents antigens to CD8+ T cells.
• Positive regulation of MHC class I biosynthesis can be driven by dietary lipids such as elaidic acid via ACSL5, boosting tumoral antigen presentation and cancer immunity.
• Quality control autophagy mediated by IRGQ targets MHC class I for degradation, and its loss promotes tumor immune evasion, showing that biosynthesis and degradation are balanced.
• NCOR2 represses MHC class I molecule expression, and its activity drives metastatic progression of breast cancer, linking transcriptional repression of MHC class I to poor outcomes.
• MHC class I on target cells regulates CD4+ T cell-mediated immunity, expanding the known roles of MHC class I beyond CD8+ T cell activation.
Description
The Gene Ontology term GO:0045345, positive regulation of MHC class I biosynthetic process, refers to any process that activates or increases the frequency, rate or extent of the chemical reactions and pathways resulting in the formation of MHC class I molecules. MHC class I molecules are cell-surface glycoproteins that present endogenous peptides to CD8+ T cells and are therefore central to adaptive immune surveillance. The biosynthetic process encompasses transcription of MHC class I heavy chain genes, assembly with beta-2-microglobulin, peptide loading in the endoplasmic reticulum, and trafficking to the plasma membrane. Positive regulation of this process can occur at multiple levels, including transcriptional activation, enhanced peptide supply, and modulation of chaperone availability. Researchers study GO:0045345 because the density of MHC class I on the cell surface determines whether a target cell is recognized and killed by cytotoxic T lymphocytes. In cancer, tumors often downregulate MHC class I biosynthesis to evade immune detection, and restoring or enhancing this process is a major goal of immunotherapy. In autoimmunity and inflammatory myopathies, excessive MHC class I expression contributes to tissue damage. Understanding the molecular players that positively regulate MHC class I biosynthesis therefore has direct implications for cancer immunotherapy, vaccine design, and autoimmune disease. This article integrates the QuickGO definition with verified PubMed literature to describe the mechanisms, key genes, disease links, and experimental models relevant to GO:0045345. It is intended for researchers who need a concise, citable overview of how MHC class I biosynthesis is positively regulated and how to study it using CRISPR-based approaches.
positive regulation of MHC class I biosynthetic process At A Glance
| GO ID | GO:0045345 |
|---|---|
| GO term | positive regulation of MHC class I biosynthetic process |
| Ontology | biological_process |
| Synonym | activation of MHC class I biosynthetic process; positive regulation of major histocompatibility complex class I biosynthesis; upregulation of MHC class I biosynthetic process |
| Major function | Increases the production of MHC class I molecules, enhancing antigen presentation to CD8+ T cells |
| Related process | MHC class I antigen presentation and quality control autophagy |
| Key regulators | ACSL5, IRGQ, NCOR2, and other factors that modulate MHC class I transcription or assembly |
| Disease relevance | Cancer immune evasion, autoimmune myositis, and metastatic progression |
What Is GO:0045345?
GO:0045345 is a biological process term defined as any process that activates or increases the frequency, rate or extent of the chemical reactions and pathways resulting in the formation of MHC class I. In simpler terms, it covers all the ways a cell can boost the production of MHC class I molecules, from increasing gene transcription to enhancing assembly and transport to the cell surface. This term is a child of positive regulation of MHC class I biosynthetic process and is distinct from negative regulation, which would decrease MHC class I production.
Why Is positive regulation of MHC class I biosynthetic process Important in Cell Biology?
Positive regulation of MHC class I biosynthetic process is critical because the amount of MHC class I on the cell surface directly determines the efficiency of CD8+ T cell recognition and killing of infected or transformed cells. Enhancing this process can improve antitumor immunity, as shown by dietary elaidic acid boosting tumoral antigen presentation via ACSL5. Conversely, tumors can evade immunity by degrading MHC class I through IRGQ-mediated autophagy or by repressing its expression via NCOR2. Therefore, understanding how to positively regulate MHC class I biosynthesis is essential for developing immunotherapies, vaccines, and treatments for autoimmune diseases where MHC class I is overexpressed.
• Determines the efficiency of CD8+ T cell-mediated killing of infected or cancerous cells.
• Enhancement of MHC class I biosynthesis can boost antitumor immunity and response to immunotherapy.
• Tumor immune evasion often involves downregulation or degradation of MHC class I, making positive regulation a therapeutic target.
• MHC class I on target cells also regulates CD4+ T cell-mediated immunity, broadening its immunological importance.
• Autoimmune conditions such as anti-Ku+ myositis are associated with aberrant MHC class I expression in muscle.
• Dietary factors like elaidic acid can positively regulate MHC class I biosynthesis through ACSL5, linking metabolism to antigen presentation.
• Quality control autophagy mediated by IRGQ negatively regulates MHC class I, highlighting the balance with positive regulation.
• Transcriptional repression by NCOR2 reduces MHC class I and drives breast cancer metastasis.
• Understanding positive regulation aids in vaccine design by increasing antigen presentation.
• CRISPR screens can identify novel positive regulators of MHC class I biosynthesis for immunotherapy targets.
What Happens During positive regulation of MHC class I biosynthetic process?
Transcriptional activation of MHC class I genes
In simple terms: The cell increases the reading of MHC class I genes to make more mRNA.
Positive regulation often begins with increased transcription of MHC class I heavy chain genes (HLA-A, HLA-B, HLA-C in humans) and beta-2-microglobulin. This can be driven by cytokines such as interferons, which activate transcription factors that bind to MHC class I promoters. In cancer, dietary elaidic acid boosts tumoral antigen presentation via ACSL5, which may involve enhanced transcription of MHC class I components. Conversely, NCOR2 represses MHC class I molecule expression, and its loss increases MHC class I levels, indicating that transcriptional repression is a key node for positive regulation.
Peptide generation and transport into the endoplasmic reticulum
In simple terms: Proteins are cut into peptides and moved into the ER to be loaded onto MHC class I.
MHC class I molecules present peptides derived from cytosolic proteins. Positive regulation of MHC class I biosynthesis can involve increased peptide supply through enhanced proteasomal degradation and TAP-mediated transport into the endoplasmic reticulum. Autophagy has also been implicated in MHC class I antigen presentation, potentially influencing peptide availability. The efficiency of peptide loading directly affects the stability and surface expression of MHC class I.
Assembly and peptide loading in the endoplasmic reticulum
In simple terms: MHC class I heavy chain, beta-2-microglobulin, and a peptide are assembled into a stable complex.
In the endoplasmic reticulum, MHC class I heavy chain associates with beta-2-microglobulin and the peptide-loading complex, including chaperones such as calnexin, calreticulin, and tapasin. Positive regulation can enhance the assembly process by increasing the availability of these components or by modulating chaperone activity. IRGQ-mediated autophagy acts as a quality control mechanism that targets MHC class I for degradation, and its inhibition can increase MHC class I surface levels, effectively positively regulating the biosynthetic process.
Trafficking to the cell surface
In simple terms: The assembled MHC class I complex is transported to the cell surface to show antigens.
After peptide loading, MHC class I molecules are transported through the Golgi to the plasma membrane. Positive regulation of the biosynthetic process can also involve increased trafficking efficiency. Once at the surface, MHC class I presents peptides to CD8+ T cells, and the density of these complexes determines the strength of T cell activation. MHC class I on target cells also regulates CD4+ T cell-mediated immunity, indicating broader roles for surface MHC class I.
Quality control and degradation balance
In simple terms: The cell checks MHC class I quality and removes defective molecules, so blocking removal increases surface levels.
MHC class I biosynthesis is balanced by quality control pathways that degrade misfolded or excess molecules. IRGQ-mediated autophagy specifically targets MHC class I for lysosomal degradation, and loss of IRGQ promotes tumor immune evasion by reducing MHC class I surface levels. Therefore, positive regulation of MHC class I biosynthetic process can be achieved by inhibiting degradation pathways, in addition to enhancing synthesis.
Key Genes Involved in GO:0045345 positive regulation of MHC class I biosynthetic process
The following genes and proteins are experimentally implicated in the positive regulation of MHC class I biosynthetic process or in related quality control and transcriptional repression mechanisms.
| Gene | Major Role | Research Relevance |
|---|---|---|
| ACSL5 | Long-chain acyl-CoA synthetase 5; mediates elaidic acid-induced boost of tumoral antigen presentation | Dietary lipid effects on MHC class I and cancer immunity |
| IRGQ | Mediates autophagy-dependent quality control of MHC class I | Tumor immune evasion; targeting IRGQ increases MHC class I |
| NCOR2 | Transcriptional corepressor that represses MHC class I molecule expression | Breast cancer metastasis; NCOR2 loss increases MHC class I |
| HLA-A | MHC class I heavy chain gene | Antigen presentation to CD8+ T cells |
| HLA-B | MHC class I heavy chain gene | Antigen presentation to CD8+ T cells |
| HLA-C | MHC class I heavy chain gene | Antigen presentation and NK cell regulation |
| B2M | Beta-2-microglobulin; essential light chain of MHC class I | MHC class I assembly and surface expression |
| TAP1 | Transporter associated with antigen processing 1 | Peptide transport into ER for MHC class I loading |
| TAP2 | Transporter associated with antigen processing 2 | Peptide transport into ER for MHC class I loading |
| PSMB8 | Immunoproteasome subunit beta 8 | Peptide generation for MHC class I |
| PSMB9 | Immunoproteasome subunit beta 9 | Peptide generation for MHC class I |
| CANX | Calnexin; chaperone for MHC class I folding | MHC class I assembly in ER |
| CALR | Calreticulin; chaperone in peptide-loading complex | MHC class I assembly in ER |
| TAPBP | Tapasin; bridges TAP and MHC class I | Peptide loading and MHC class I stability |
| PDIA3 | Protein disulfide isomerase A3; part of peptide-loading complex | MHC class I assembly |
| NLRC5 | Transcriptional activator of MHC class I genes | Positive regulation of MHC class I transcription |
| CIITA | Master regulator of MHC class II, also affects class I in some contexts | Transcriptional regulation of antigen presentation |
How Is positive regulation of MHC class I biosynthetic process Regulated?
Positive regulation of MHC class I biosynthetic process is controlled at multiple levels. Transcriptional activation by cytokines such as interferons and by NLRC5 increases MHC class I gene expression. Metabolic signals, such as elaidic acid via ACSL5, can boost antigen presentation in tumors. Quality control autophagy mediated by IRGQ negatively regulates MHC class I by targeting it for degradation, so inhibition of IRGQ enhances MHC class I levels. Transcriptional repression by NCOR2 reduces MHC class I expression, and its loss increases MHC class I, indicating that relief of repression is a form of positive regulation. Together, these mechanisms fine-tune MHC class I surface density to balance immune surveillance and evasion.
positive regulation of MHC class I biosynthetic process and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| ACSL5 | Cancer immunity and antigen presentation | ACSL5 knockout or overexpression in tumor cells |
| IRGQ | Tumor immune evasion via MHC class I degradation | IRGQ knockout in cancer cell lines |
| NCOR2 | Breast cancer metastasis and MHC class I repression | NCOR2 knockout or knockdown in breast cancer cells |
| B2M | MHC class I deficiency and immune evasion | B2M knockout in tumor models |
| NLRC5 | Transcriptional regulation of MHC class I | NLRC5 overexpression or knockout |
Cancer immune evasion and immunotherapy
Tumors frequently downregulate MHC class I to evade CD8+ T cell killing, and positive regulation of MHC class I biosynthesis can restore immune recognition. Dietary elaidic acid boosts tumoral antigen presentation via ACSL5, enhancing cancer immunity. IRGQ-mediated autophagy degrades MHC class I and promotes tumor immune evasion, so targeting IRGQ could increase MHC class I and improve immunotherapy. NCOR2 represses MHC class I expression and drives metastatic progression of breast cancer, linking transcriptional repression to poor outcomes.
Autoimmune and inflammatory myopathies
Aberrant overexpression of MHC class I in muscle is a feature of inflammatory myopathies such as anti-Ku+ myositis, where MHC class I upregulation contributes to tissue damage. Understanding positive regulation of MHC class I biosynthesis may provide insights into the pathogenesis of these diseases.
Thyroid autoimmunity
The thyrotropin receptor is a key autoantigen in Graves' disease, and MHC class I presentation of its peptides may be involved in autoimmune thyroid disease. Positive regulation of MHC class I biosynthesis could influence the presentation of thyroid autoantigens.
Anaplastic thyroid cancer and MAPK inhibitor insensitivity
Loss of tumor cell MHC class II drives MAPK inhibitor insensitivity in BRAF-mutant anaplastic thyroid cancers, and MHC class I may also play a role in immune escape. Modulating MHC class I biosynthesis could affect responses to targeted therapies.
From positive regulation of MHC class I biosynthetic process-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of a candidate gene increase MHC class I surface levels? | CRISPR knockout in cancer cell lines followed by flow cytometry |
| Does a point mutation in a regulator alter MHC class I biosynthesis? | CRISPR point mutation knock-in |
| Does overexpression of a transcription factor boost MHC class I? | CRISPR knock-in of a constitutive promoter or cDNA overexpression |
| Where does a regulator localize relative to MHC class I? | Tagged knock-in with fluorescent protein |
| Can a dietary metabolite enhance antigen presentation? | ACSL5 knockout and elaidic acid treatment in tumor cells |
| Does autophagy inhibition increase MHC class I? | IRGQ knockout with autophagy flux assays |
How to Study the positive regulation of MHC class I biosynthetic process Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Flow cytometry | Surface MHC class I protein levels | Quantify positive regulation after gene knockout |
| RNA-seq | mRNA levels of MHC class I and related genes | Transcriptional profiling |
| qPCR | Specific mRNA transcript levels | Validate changes in MHC class I gene expression |
| Immunoprecipitation | Protein-protein interactions in MHC class I assembly | Identify chaperone complexes |
| Mass spectrometry | Proteome-wide changes and interactors | Discover novel regulators |
| CRISPR screen | Genome-wide regulators of MHC class I surface levels | Identify positive regulators for immunotherapy |
| Autophagy flux assay | Degradation of MHC class I via autophagy | Study IRGQ-mediated quality control |
| Luciferase reporter assay | Promoter activity of MHC class I genes | Measure transcriptional activation |
Flow cytometry for surface MHC class I
Flow cytometry using antibodies against MHC class I heavy chain or beta-2-microglobulin is the standard method to measure surface MHC class I levels after genetic perturbation. This method quantifies the positive regulation of MHC class I biosynthetic process at the protein level on the cell surface.
RNA sequencing and quantitative PCR
RNA-seq and qPCR measure mRNA levels of MHC class I genes (HLA-A, HLA-B, HLA-C, B2M) and related regulators, providing insight into transcriptional positive regulation. These methods can identify changes in gene expression after knockout or overexpression of candidate regulators.
Proteomics and immunoprecipitation
Mass spectrometry-based proteomics and immunoprecipitation can identify proteins associated with MHC class I and quantify changes in assembly complex components. These approaches help define the molecular machinery of positive regulation.
CRISPR library screening
Genome-wide CRISPR knockout or activation screens coupled with MHC class I surface staining can identify novel positive and negative regulators of MHC class I biosynthesis. Such screens have revealed ACSL5 and IRGQ as modulators of antigen presentation and immune evasion.
How CRISPR Can Be Used to Study GO:0045345 positive regulation of MHC class I biosynthetic process
Knockout
CRISPR knockout of candidate genes such as IRGQ or NCOR2 can increase MHC class I surface levels, confirming their role as negative regulators whose loss positively regulates MHC class I biosynthesis. Knockout of B2M abolishes MHC class I surface expression and serves as a control.
Point Mutation
CRISPR point mutation knock-in can introduce specific amino acid changes in regulators like ACSL5 to test their function in boosting antigen presentation. This approach helps dissect catalytic versus scaffolding roles.
Knock-in
CRISPR knock-in of fluorescent tags on MHC class I heavy chain or beta-2-microglobulin allows real-time imaging of biosynthesis and trafficking. Knock-in of a constitutive promoter can drive overexpression of positive regulators.
Overexpression
CRISPR activation (CRISPRa) or cDNA overexpression can increase the levels of transcription factors like NLRC5 to boost MHC class I biosynthesis. Overexpression of ACSL5 may enhance elaidic acid-induced antigen presentation.
How EDITGENE Supports positive regulation of MHC class I biosynthetic process Research
Researchers studying positive regulation of MHC class I biosynthetic process-related genes often need to determine whether a candidate gene is causally involved in boosting MHC class I levels, and CRISPR-based models provide the most direct way to test this. EDITGENE offers a comprehensive suite of services to support such studies.
Contact EDITGENE today to design your custom CRISPR model for positive regulation of MHC class I biosynthetic process research.
Frequently Asked Questions About positive regulation of MHC class I biosynthetic process
What is GO:0045345?
GO:0045345 is the Gene Ontology term for positive regulation of MHC class I biosynthetic process, defined as any process that activates or increases the frequency, rate or extent of the formation of MHC class I molecules.
What genes are involved in positive regulation of MHC class I biosynthetic process?
Key genes include ACSL5, IRGQ, NCOR2, HLA-A, HLA-B, HLA-C, B2M, TAP1, TAP2, and NLRC5, among others.
How does elaidic acid affect MHC class I?
Dietary elaidic acid boosts tumoral antigen presentation and cancer immunity via ACSL5, positively regulating MHC class I biosynthesis.
What is the role of IRGQ in MHC class I?
IRGQ mediates autophagy-dependent quality control of MHC class I, targeting it for degradation; loss of IRGQ promotes tumor immune evasion.
How does NCOR2 regulate MHC class I?
NCOR2 represses MHC class I molecule expression, and its activity drives metastatic progression of breast cancer.
Why is MHC class I important for CD4+ T cells?
MHC class I on target cells regulates CD4+ T cell-mediated immunity, indicating a broader role beyond CD8+ T cell activation.
What diseases are linked to MHC class I biosynthesis?
Cancer immune evasion, autoimmune myositis, and thyroid autoimmunity are linked to altered MHC class I biosynthesis.
How can I study positive regulation of MHC class I in the lab?
Use flow cytometry, RNA-seq, CRISPR screens, and knockout models to measure MHC class I surface levels and identify regulators.
What CRISPR models are available for MHC class I research?
Knockout, point mutation, knock-in, and overexpression models can be generated for genes like ACSL5, IRGQ, and NCOR2.
What is the role of autophagy in MHC class I presentation?
Autophagy is involved in MHC class I antigen presentation and quality control, with IRGQ-mediated autophagy degrading MHC class I.
Conclusion
GO:0045345, positive regulation of MHC class I biosynthetic process, is a central node in immune surveillance and cancer immunotherapy. The balance between synthesis, assembly, and degradation of MHC class I determines whether target cells are recognized by T cells. Key regulators such as ACSL5, IRGQ, and NCOR2 provide opportunities for therapeutic intervention to boost antigen presentation and overcome immune evasion. Continued research using CRISPR models and multi-omics approaches will further elucidate how to harness this process for clinical benefit.
References
- 1. Lai Y et al.. 2024. Dietary elaidic acid boosts tumoral antigen presentation and cancer immunity via ACSL5.. Cell Metab 36(4):822-838.e8 PMID: 38350448
- 2. Herhaus L et al.. 2024. IRGQ-mediated autophagy in MHC class I quality control promotes tumor immune evasion.. Cell 187(25):7285-7302.e29 PMID: 39481378
- 3. Lauder E et al.. 2026. MHC class I on target cells regulates CD4(+) T cell-mediated immunity.. Nat Immunol 27(5):1000-1012 PMID: 41876718
- 4. Tiedje V et al.. 2025. Loss of tumor cell MHC class II drives MAPK inhibitor insensitivity of BRAF-mutant anaplastic thyroid cancers.. J Clin Invest 135(20) PMID: 40828595
- 5. Holzer MT et al.. 2024. Anti-Ku + myositis: an acquired inflammatory protein-aggregate myopathy.. Acta Neuropathol 148(1):6 PMID: 39012547
- 6. Øynebråten I. 2020. Involvement of autophagy in MHC class I antigen presentation.. Scand J Immunol 92(5):e12978 PMID: 32969499
- 7. Kohn LD et al.. 1995. The thyrotropin receptor.. Vitam Horm 50:287-384 PMID: 7709602
- 8. Ticha P et al.. 2026. NCOR2 represses MHC class I molecule expression to drive metastatic progression of breast cancer.. Nat Commun 17(1) PMID: 42086546
